

BEST AVAILABLE COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, 5/10, C07K 14/705, C12Q 1/00		A2	(11) International Publication Number: WO 96/39512 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/US96/08835 (22) International Filing Date: 4 June 1996 (04.06.96)		(81) Designated States: AU, CA, CZ, EE, HU, IL, JP, LT, LV, MX, NZ, PL, RO, SG, SI, SK, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/467,203 6 June 1995 (06.06.95) US (60) Parent Application or Grant (63) Related by Continuation US Filed on 08/467,203 (CIP) 6 June 1995 (06.06.95)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			
(54) Title: A CELL LINE FOR THE RAPID EXPRESSION OF FUNCTIONAL CALCIUM CHANNELS			
(57) Abstract			
The instant invention provides a stable cell line, 348932L, for the rapid functional expression of high voltage activated calcium channels.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**A CELL LINE FOR THE RAPID EXPRESSION OF
FUNCTIONAL CALCIUM CHANNELS**

FIELD OF THE INVENTION

5

The invention pertains to a cell line for the rapid expression of functional calcium channels.

BACKGROUND OF THE INVENTION

10

The voltage activated calcium channels of vertebrates have been shown to be involved in a variety of different physiological processes including muscle contraction, insulin release from the pancreas, and neurotransmitter release in the nervous system (Catterall W.A., Trends in Neurosciences, 1993;16:500-506; Catterall W., Epstein P.N., Diabetologia, 35(Suppl 2:S23-33) 1992; Birnbaumer L., et al., Neuron, 1994:13; Rorsman P., et al., Diabete. Metab., 1994;20:138-145). The original description of the calcium channels classed them as T type, L type, or N type. The T type channel is activated at relatively low voltages, while the L and N types are activated by depolarization to higher voltages. The L type is a channel that is involved in muscle contraction, and is characterized by slow inactivation and sensitivity to dihydropyridines. The N type is also a high voltage activated channel, but rather than being sensitive to dihydropyridines, the N channel is blocked by the peptide toxins GVIA, MVIIA, and MCVIIC from cone snails, and is involved in neurotransmitter release (Birnbaumer L., et al., Neuron, 1994:13; Olivera B.M., Miljanich G.P., Ramachandran J., Adams M.E., Annu Rev. Biochem., 1994;63:823-867).

35

The channels purified from neural tissue and skeletal muscle contain a number of different subunits. The L channel from skeletal muscle consists of a

-2-

complex containing five subunits, alpha 1, alpha 2, beta, delta, and gamma. L channels isolated from neuronal tissue consist of three subunits corresponding to the alpha 1, alpha 2/delta, and beta subunits.

5 Gamma does not seem to be expressed in the nervous system (Catterall W.A., Trends in Neurosciences, 1993;16:500-506).

10 The N type channel is expressed primarily in neuronal tissue, though there have been some reports of the channel being expressed in beta cells of the pancreas. The N channel is also made up of alpha 1, alpha 2/delta, and beta subunits.

15 Recent experiments have shown that there are a number of other calcium channels in the central nervous system. The P type channel has been described in cerebellar Purkinje cells. This channel is a high voltage activated channel, but it differs from the 20 N and L types primarily in its insensitivity to either dihydropyridines or conotoxins. Instead, this channel is sensitive to the peptide toxin Aga IVA from the funnel web spider. Cerebellar granule cells express a high voltage activated channel that has been called R 25 and is insensitive to Aga IVA, the conotoxins MVIIA and GVIA, and dihydropyridines. (Birnbaumer L., et al., Neuron, 1994:13).

30 Molecular cloning of the channel subunits from skeletal muscle and brain have revealed a significant similarity between the various different calcium channel subtypes. The level of conservation between the alpha 1 subunits of the N and L types is quite high, and this subunit has been identified as the 35 subunit through which calcium ions flow. Several isoforms of alpha 2/delta and beta subunit clones have

-3-

also been isolated from neuronal and muscle tissue,
though there has been no definite assignment of
specific isoforms to a particular type of calcium
channel. As yet, there is no definite assignment of
5 the P/Q type to a cloned cDNA.

Expression experiments in *Xenopus* oocytes
have demonstrated that in order to produce fully
functional calcium channels, the alpha 1, alpha
10 2/delta, and beta subunits must all be expressed.
Absence of either the alpha 2/delta or beta subunit
results in a nonfunctional channel, even though the
alpha 1 subunit, through which ions flow, is fully
expressed. Indeed, not only the ion flux through these
15 channels but the pharmacological properties of the
alpha 1 are different in the absence of the alpha
2/delta and beta subunits. Expression of an alpha 1
subunit with different beta subunits results in
channels with different inactivation properties,
20 indicating that the beta-alpha 1 interaction is
important in regulating the functional properties of
the channels.

Expression of calcium channels in mammalian
25 cells has lagged behind expression in *Xenopus* oocytes
in part because *Xenopus* oocyte expression is quite
convenient and in part because stable expression in
mammalian cells has proven difficult. Many properties
30 of the channels can be analyzed by electrophysiological
techniques in *Xenopus* oocytes, and some pharmacology
can be done using this system. Mammalian expression
would allow a better characterization of the binding
properties of drugs and peptides. Yet it has proven
35 difficult to generate stable cell lines; whether
because of an intrinsic toxicity of the expressed
channel, or the combinatorial problem of expressing

-4-

three subunits simultaneously in a single cell. Indeed, some authors have speculated that it is not possible to generate a set of cells which are stably expressing calcium channels at high levels.

5 (Brust P.F., et al., Neuropharmacology, 1993;32).

Transient expression has been obtained by a number of different groups. While these systems have allowed some further pharmacological characterization
10 of the expressed channels, they are difficult to carefully reproduce from time to time, and depend on each of three different subunits being expressed in the same cells (Brust P.F., et al., Neuropharmacology, 1993;32; Williams M.E., et al., J. Biol. Chem.,
15 1994;269:22347-22357)

One utility of cells expressing the alpha 2/delta and beta subunits of the calcium channel is in the area of transient expression. Recent work has
20 identified regions of the calcium channel to which the conopeptides bind. These analyses were performed in *Xenopus* oocytes. In this system one can only measure the rates at which the peptides bind to the channel (Ellinor P.T., Zhang J.F., Horne W.A., Tsien R.W.
25 Nature, 1994;372). Transient expression of these alpha 1 subunits in cells that are expressing the alpha 2 and beta subunits would allow for equilibrium binding measurements to be performed, allowing for more complete evaluation of the interaction between the
30 channel and the peptides.

WO 95/04822 teaches isolated cDNAs encoding each of human calcium channel alpha 1 to alpha 2, beta, and gamma subunits, including subunits that arise as splice variants of primary transcripts. In particular, DNA clones encoding each of the alpha 1A-1, alpha 1A-2,
35

-5-

alpha 1E-1, alpha 1C-2, alpha 1E-3, beta 3-1, beta 2C, beta 2D, beta 2E, and beta 4 subunits of human calcium channels are provided.

5 United States Patent Number 5,386,025 teaches calcium channel gamma subunit encoding cDNAs.

10 The instant invention of developing stable cell lines expressing calcium channels by generating cells in which two of the subunits are expressed at high levels and using the 348932L cells to transfect in the alpha subunit for any calcium channel to obtain cells expressing a new calcium channel type is not taught by the references.

15

SUMMARY OF THE INVENTION

20 The purpose of the instant invention is the development of cell lines that allow the rapid development of cell lines that are stably expressing a variety of different calcium channels.

25 The instant invention overcomes the difficulty in developing stable cell lines expressing calcium channels which is due in large part to obtaining stable incorporation of three different subunit clones in a single cell line. By generating cells in which two of the three subunits are expressed at high levels, generation of cell lines that express high levels of channels has been greatly simplified. Now, using the 348932L cells, one can simply transfect in the alpha 1 subunit for any of the different calcium channels and have cells expressing a new calcium channel type.

35

-6-

The 348932L cells are useful for developing clonal cell lines expressing calcium channels.

5 The 348932L cells are for the general expression of high voltage activated calcium channels of a variety of types including but not limited to N type channels, R type channels, Q type channels, and cardiac Class C, L type channels.

10

BRIEF DESCRIPTION OF THE DRAWING

FIGURE 1 is a northern blot analysis of the RNA from several cell lines transfected with alpha 2 and beta subunit clones.

15

FIGURE 2 is electrophysiological analysis of the C class channel expressed in the two L cells.

FIGURE 3 is a comparison of currents.

20

FIGURE 4 is the utility of the 348932 L cells.

-7-

DETAILED DESCRIPTION OF THE INVENTION

MATERIALS AND METHODS

5 Lipofectamine, RPMI 1640 medium, Optimem-1 medium, fetal bovine serum, and the antibiotic Geneticin (G418) were obtained from Life Technologies Inc.

10 Human embryonic kidney cells (HEK 293 cells, ATCC# CRL 1573) were obtained from the American Type Culture Collection. The cells are maintained in RPMI (Roswell Park Memorial Institute) 1640 medium supplemented with 2 mM glutamine and 10% fetal bovine serum.

15 The antibiotic Hygromycin B sulfate was obtained from Boehringer Mannheim.

20 cDNAs for the rabbit skeletal muscle calcium channel alpha 2 subunit, and the human neuronal beta 2 subunit cloned into the expression vector pcDNAIII (Invitrogen) were obtained from Neurex. Human neuronal calcium channel alpha 1 subunits of E class and B class, cloned into the expression vector pcDNAIII, were obtained from Neurex.

25 HEK 293 cells were maintained in RPMI 1640 medium supplemented with 2 mM glutamine and 10% fetal bovine serum. One day prior to transfections, cells were washed with 12 ml of Dulbecco's Phosphate Buffered Saline (Life Technologies) and then treated with a solution of 0.25% Trypsin for 5 minutes at room temperature to release the cells from the plate, and the cells were then counted. Cells were plated at a density of 300,000 to 500,000 cells per well in six well plates.

-8-

Cells were transfected using lipofectamine mediated transfection. Per well, 2 μ g of neuronal beta-2 plasmid, and 2 μ g of alpha 2 containing plasmid were mixed in 100 mL of Optimem-1 medium. Twenty-five
5 microliters of lipofectamine at a concentration of 2 mg/mL was added to a separate aliquot of Optimem-1. The DNA containing medium and the lipofectamine containing medium was mixed and allowed to incubate at room temperature for 45 minutes. Eight hundred
10 microliters of Optimem-1 medium was added per 200 mL of lipofectamine-DNA mixture. Cells in six well plates were washed once with Optimem-1, and then the DNA-lipofectamine mixture was layered onto the cells. The cells were incubated overnight at 37°C.

15

After overnight incubation, the cells were washed once with Optimem-1 medium, then RPMI 1640 medium supplemented with 2 mM glutamine, and 10% fetal bovine serum was added to the cells. The cells
20 remained in this nonselective medium for 2 days, then RPMI 1640 medium supplemented with 2 mM glutamine, and 10% fetal bovine, and also supplemented with Geneticin at a concentration of 600 μ g/mL was added.

25

After 3 to 4 weeks of selection in this medium, cells which were resistant to G418 began to form colonies. Cloning cylinders were placed around the colonies, and the colonies were trypsinized. Each colony was then placed into separate wells of a 24 well plate and allowed to grow to confluence. After reaching confluence, each well was trypsinized, and transferred into two wells of a six well plate. After these wells reached confluence, each well was trypsinized, and one was frozen. The second well was used to seed two wells of a six well plate.

35

-9-

Cells in one of the duplicate wells were lysed in a guanidine thiocyanate solution and hybridized in an RNase Protection assay overnight at 65° C in a hybridization solution containing guanidine isothiocyanate(Ambion) with probes labeled with ^{32}P prepared by *in vitro* transcription from the alpha 2 and beta clones used in the transfections. Cell lines showing hybridization to either of these probes were expanded and RNA was prepared for northern blot analysis.

Cell lines that were expressing high levels of both alpha 2/delta and beta messenger RNA were expanded and used for subsequent transfections. The cells were maintained in selective medium consisting of RPMI 1640 medium supplemented with 2 mM glutamine, and 10% fetal bovine serum, and also supplemented with Geneticin(G418) at a concentration of 600 $\mu\text{g}/\text{mL}$. Transfections of the B class and E class alpha 1 subunits were accomplished essentially as above, but the plasmid pREP4(Invitrogen)containing the gene for hygromycin resistance was co-transfected with the plasmids containing the cDNAs for the B and E class alpha 1 subunits. Selection was in medium containing G418 at a concentration of 600 $\mu\text{g}/\text{mL}$, and Hygromycin B sulfate at a concentration of 400 $\mu\text{g}/\text{mL}$. Cells were selected in this medium and characterized for expression of functional calcium channels by electrophysiological methods.

348932L cells were characterized for the binding of ^3H -Gabapentin. Binding of ^3H -Gabapentin was measured by incubation of membranes at a protein concentration of 30 μg with 20 nM ^3H -Gabapentin (Amersham, 61 Ci/mmol) in 10 mM HEPES buffer, pH 7.4 for 30 minutes at 22° C. Binding was terminated by addition

-10-

- of 5 ml of ice cold 100 mM NaCl, followed by filtration through Whatman GFB filters. Filters were then washed twice with 5 ml of ice cold 100 mM NaCl. filters were dried, then counted by liquid scintillation counting.
- 5 Non-specific binding was determined in the presence of 100 μ M Gabapentin.

Figure 1 presents the results of the northern blot analysis of the RNA from several cell lines transfected with alpha 2 and beta subunit clones. It can be seen that the level of expression of these two subunits varies quite a bit from one transfected line to another. All of the cell lines showed positive for alpha 2 and beta in RNase protections, but each is expressing different amounts of the RNA.

The 348932L cell line is expressing the highest levels of both the alpha 2 and the beta subunit RNAs, and it was chosen as the vehicle for transfecting 20 in B and E class alpha 1 clones.

Figure 2 presents the results of electrophysiological analysis of the E class channel expressed in the 348932L cells. The channels expressed 25 in these cells exhibits the standard electrophysiological properties of the E class channel. The channel is activated at high depolarizations (in this case a current step to 10 mV from a holding potential of -80 mV), the inactivation is relatively 30 slow, and the channel is blocked by 10 μ M Cd²⁺.

Figure 3 shows a comparison of the currents from S3 cells (348932L cells which have been transfected with the B class, or N type alpha 1) and 35 192C cells(348932L cells transfected with the E class alpha 1). As can be seen, the cells express channels

-11-

that are similar, but differ slightly in their activation kinetics, and inactivation kinetics.

Figure 4 illustrates the utility of the
5 348932L cells in looking at the binding of Neurontin to the alpha 2 subunit of the calcium channel. The level of specific binding to the transfected cells is about 20 times higher than that seen in the parent, untransfected HEK 293 cells.

10

One of the distinct advantages of the present invention is the ability to determine the ability of a sample compound to be an antagonist to Gabapentin in the cell line described herein. The invention can therefore be characterized as the following:

15 a method for determining an antagonist ability of a sample material comprising:
providing a vessel containing a calcium channel that simultaneously expresses an alpha 2/delta subunit, and beta subunit;

20 introducing into the vessel gabapentin;
introducing a sample material having the ability to antagonize or not antagonize gabapentin's binding ability to the cell line by competitive binding; and

25 determining the binding ability of the sample material.

While the forms of the invention herein disclosed constitute presently preferred embodiments, many others are possible. It is not intended herein to mention all of the possible equivalent forms or ramifications of the invention. It is understood that the terms used herein are merely descriptive rather

-12-

than limiting and that various changes may be made without departing from the spirit or scope of the invention.

-13-

WHAT IS CLAIMED IS:

1. A method of expressing simultaneously calcium channels comprising the steps of:

5 (1) providing a cell in which an alpha 2/delta subunit and a beta subunit of a calcium channel are expressed;

(2) transfecting into the cell of step (1) an alpha 1 subunit of a calcium channel; and

10 (3) expressing in the transfected cells simultaneously the three calcium channel units.

2. The method of claim 1 wherein the three calcium channel subunits are alpha 1, alpha 2/delta, and beta subunits.

15 3. The method of claim 1 wherein the simultaneous calcium channel being expressed is an N-type calcium channel.

20 4. A cell line identified as 3489321 having ATCC No. _____ CRL.

25 5. The cell line of claim 4 wherein the cell line has the ability to express functional calcium channels.

6. The cell line of claim 4 wherein the cells are mammalian cells.

30 7. A method of expressing high voltage activated calcium channels comprising:

providing a cell line that simultaneously expresses alpha 2/delta subunit and beta subunits; and

-14-

transfected into the aforementioned cell an alpha 1 calcium channel subunit thereby generating an N-type calcium channel.

5 8. A method of expressing high voltage activated calcium channels comprising:

providing a cell line that simultaneously expresses alpha 2/delta subunit and beta subunits; and
transfected into the aforementioned cell an
10 alpha 1 calcium channel subunit thereby generating an R-type calcium channel.

9. A method of expressing high voltage activated calcium channels comprising:

15 providing a cell line that simultaneously expresses alpha 2/delta subunit and beta subunits; and
transfected into the aforementioned cell an
alpha 1 calcium channel subunit thereby generating a
P/Q-type calcium channel.

20 20 10. A method of expressing high voltage activated calcium channels comprising:

providing a cell line that simultaneously expresses alpha 2/delta subunit and beta subunits; and
25 transfected into the aforementioned cell an
alpha 1 calcium channel subunit thereby generating an
L-type calcium channel.

30 30 11. A method of expressing high voltage activated calcium channels comprising:

providing a cell line that simultaneously expresses alpha 2/delta subunit and beta subunits; and
transfected into the aforementioned cell an
alpha 1 calcium channel subunit thereby generating a
35 cardiac L-type calcium channel.

-15-

12. A method of expressing high voltage activated calcium channels comprising:

providing a cell line that simultaneously expresses alpha 2/delta subunit and beta subunits; and

5 transfecting into the aforementioned cell an alpha 1 calcium channel subunit which has been

mutagenized in vitro by oligonucleotide directed

mutagenesis in which a mutant oligonucleotide is synthesized containing the mutant of interest,

10 hybridizing the mutant oligonucleotide to the wild-type alpha 1 sequence, and extending the primer in vitro.

13. A method for determining an antagonist ability of a sample material comprising:

15 providing a vessel containing a calcium channel that simultaneously expresses an alpha 2/delta subunit, and beta subunit;

introducing into the vessel gabapentin;

introducing a sample material having the


20 ability to antagonize or not antagonize gabapentin's binding ability to the cell line by competitive binding; and

determining the binding ability of the sample material.

1/6

FIG-1 A

2A 2E 2J 2K 2L 1J 1K 1L



2A 2E 2J 2K 2L 1J 1K 1L



2/6




FIG-2

3/6






FIG-2A

4/6




5 / 6



6/6

FIG-4



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/12, 5/10, C07K 14/705, C12Q 1/00</p>		A3	<p>(11) International Publication Number: WO 96/39512</p> <p>(43) International Publication Date: 12 December 1996 (12.12.96)</p>
<p>(21) International Application Number: PCT/US96/08835</p> <p>(22) International Filing Date: 4 June 1996 (04.06.96)</p> <p>(30) Priority Data: 08/467,203 6 June 1995 (06.06.95) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/467,203 (CIP) Filed on 6 June 1995 (06.06.95)</p> <p>(71) Applicant (<i>for all designated States except US</i>): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>): OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>		<p>(81) Designated States: AU, CA, CZ, EE, HU, IL, JP, LT, LV, MX, NZ, PL, RO, SG, SI, SK, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 20 February 1997 (20.02.97)</p>	
<p>(54) Title: A CELL LINE FOR THE RAPID EXPRESSION OF FUNCTIONAL CALCIUM CHANNELS</p> <p>(57) Abstract</p> <p>The instant invention provides a stable cell line, 348932L, for the rapid functional expression of high voltage activated calcium channels.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 96/08835

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/12 C12N5/10 C07K14/705 C12Q1/00
--

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,95 04822 (THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC.) 16 February 1995 cited in the application see page 9, last paragraph - page 12, paragraph 1 see page 21, paragraph 3 see page 43, last paragraph - page 45, paragraph 1 see page 48, paragraph 2 - page 49, paragraph 1; example IX ---	1-7,9-12
X	WO,A,93 04083 (SALK INST BIOTECH IND) 4 March 1993 see page 8, line 12 - page 10, line 5 see page 37, line 3 - page 43, line 25; example VII ---	1-3,7 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

7 January 1997

17. 01. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

Intell. Appl. No.
PCT/US 96/08835

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. PHYSIOL. (LONDON) (1993), 471, 749-65 CODEN: JPHYA7;ISSN: 0022-3751, 1993, XP000603623 WELLING, ANDREA ET AL: "Stable co-expression of calcium channel. alpha.1., beta. and. alpha.2/.delta. subunits in a somatic cell line" see page 750, paragraph 2 - page 751, paragraph 1 see page 752, paragraph 4 - page 764, paragraph 1 ---	1-12
A	EP,A,0 556 651 (BAYER AG) 25 August 1993 see page 3, line 5 - line 15 ---	13
P,X	DATABASE WPI Section Ch, Week 9612 Derwent Publications Ltd., London, GB; Class B04, AN 96-110269 XP002015064 "Cells stably expressing a gene for potential-dependent calcim channel for screening calcium antagonists" & JP,A,08 009 969 (EISAI CO LTD) , 16 January 1996 see abstract ---	1,2
P,X	WO,A,96 03122 (WARNER-LAMBERT COMPANY) 8 February 1996 see page 3, line 10 - line 36 ---	13
P,X	J. BIOL. CHEM. (1996), 271(10), 5768-76 CODEN: JBCHA3;ISSN: 0021-9258, 1996, XP002022221 GEE, NICOLAS S. ET AL: "The novel anticonvulsant drug, gabapentin (Neurontin), binds to the.alpha.2.delta. subunit of a calcium channel" see abstract see page 575, right-hand column, paragraph 4 - left-hand column, paragraph 3 -----	13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/08835

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- claims 1-12: Method of expressing simultaneously calcium channel and cell therefor
- claim 13 : Method for determining an antagonist ability of a sample material

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/08835

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9504822	16-02-95	AU-A-	7632294	28-02-95
		EP-A-	0716695	19-06-96
		GB-A-	2284814	21-06-95
-----	-----	-----	-----	-----
WO-A-9304083	04-03-93	US-A-	5429921	04-07-95
		AU-A-	2495792	16-03-93
		CA-A-	2113203	04-03-93
		EP-A-	0598840	01-06-94
		JP-T-	6509717	02-11-94
-----	-----	-----	-----	-----
EP-A-0556651	25-08-93	DE-A-	4222126	19-08-93
		AT-T-	124723	15-07-95
		CA-A-	2085502	18-08-93
		DE-D-	59300318	10-08-95
		ES-T-	2075727	01-10-95
		JP-A-	6078773	22-03-94
-----	-----	-----	-----	-----
WO-A-9603122	08-02-96	AU-A-	3006995	22-02-96
		ZA-A-	9506229	11-03-96
-----	-----	-----	-----	-----

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.